Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA) has announced an inducement grant award to a new employee under its 2024 Inducement Plan. The grant consists of 3,521 restricted stock units (RSUs) of Intellia's common stock, which will vest in three equal installments on December 1 of 2025, 2026, and 2027. The award was granted outside of Intellia's stockholder-approved equity incentive plans and was approved by the company's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha annunciato l'assegnazione di un premio di indennità a un nuovo dipendente nell'ambito del suo Piano di Indennità 2024. Il premio consiste in 3.521 unità di azioni vincolate (RSU) del capitale sociale di Intellia, che matureranno in tre rate uguali il 1° dicembre del 2025, 2026 e 2027. L'assegnazione è stata concessa al di fuori dei piani di incentivazione azionaria approvati dagli azionisti di Intellia ed è stata approvata dal comitato per la retribuzione dell'azienda in conformità alla Regola di Quotazione Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha anunciado una concesión de indemnización a un nuevo empleado bajo su Plan de Indemnización 2024. La concesión consta de 3.521 unidades de acciones restringidas (RSUs) de las acciones ordinarias de Intellia, que se adjudicarán en tres partes iguales el 1 de diciembre de 2025, 2026 y 2027. El premio se otorgó fuera de los planes de incentivos de equidad aprobados por los accionistas de Intellia y fue aprobado por el comité de compensación de la compañía de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA)는 2024 유인 계획에 따라 새로운 직원에게 유인 보상 금을 발표했습니다. 이 보상은 3,521개의 제한 주식 유닛(RSU)으로 구성되어 있으며, 2025년, 2026년, 2027년 12월 1일에 세 번의 동일한 분할 방식으로 지급됩니다. 이 보상은 Intellia의 주주 승인 자본 인센티브 계획 외부에서 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 회사 보상 위원회에 의해 승인되었습니다.
Intellia Therapeutics (NASDAQ:NTLA) a annoncé une attribution d'incitation à un nouvel employé dans le cadre de son Plan d'incitation 2024. Le prix se compose de 3.521 unités d'actions restreintes (RSU) des actions ordinaires d'Intellia, qui seront acquises en trois versements égaux le 1er décembre 2025, 2026 et 2027. L'attribution a été accordée en dehors des plans d'incitation en actions approuvés par les actionnaires d'Intellia et a été approuvée par le comité de rémunération de l'entreprise conformément à la Règle de cotation Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) hat eine Anreizvergütung für einen neuen Mitarbeiter im Rahmen seines Anreizplans 2024 angekündigt. Die Vergütung besteht aus 3.521 eingeschränkten Aktieneinheiten (RSUs) der Stammaktien von Intellia, die in drei gleichen Raten am 1. Dezember 2025, 2026 und 2027 fällig werden. Die Vergabe erfolgte außerhalb der von den Aktionären genehmigten Eigenkapitalanreizpläne von Intellia und wurde gemäß der Nasdaq-Listing-Regel 5635(c)(4) vom Vergütungsausschuss des Unternehmens genehmigt.
- None.
- None.
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2024, it awarded an inducement grant to one new employee under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 3,521 shares of Intellia’s common stock, with one-third of such RSUs vesting on December 1, 2025, 2026, and 2027.
All equity vesting is subject to the employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
The above-described award was granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. The award was approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Lina Li
Senior Director, Investor Relations and Corporate Communications
lina.li@intelliatx.com
FAQ
What type of inducement grant did Intellia Therapeutics (NTLA) award on December 1, 2024?
How will the RSUs granted by Intellia Therapeutics (NTLA) vest?
Under which plan did Intellia Therapeutics (NTLA) issue the December 2024 inducement grant?
